About Us
Hermay Labs Corporation
Hermay Labs Corporation is located in Edmonton, the capital city of beautiful Alberta, Canada. Our scientific team consists of experts in several disciplines:
1. Molecular modelling: Expertise in protein dynamics, protein-ligand docking, ligand characterization predictions enables us to design and generate novel small molecules to target proteins of interest.
2. Artificial intelligence: Skilled handling of proprietary software to predict toxicity, Absorption, Distribution, Metabolism and Excretion (ADME) and pharmacokinetics (PK) in silico, before the chemical synthesis of the compounds commences, greatly reduces the cost and increases the probability of success. This software can also be used to generate novel analogs to cover every angle of potential chemical space for IP protection.
3. Medicinal and synthetic chemistry: Each of Hermay’s leading scientists has over 20 years of synthetic chemistry and medicinal chemistry experience. This experience helps to effectively identify and meet medicinal and synthetic chemistry challenges.
4. Biochemistry: Expertise in protein biochemistry and molecular mechanics ensures front line performance, not only in identifying and addressing protein targets, but in carrying out associated cell-based assays and evaluating cellular mechanisms.
Junzhi (John) Yao, Ph.D., President
Dr. Yao obtained his Ph.D. in chemistry from Wuhan University, a highly respected institution in China. He subsequently served as an Assistant Professor at Wuhan University and Visiting Scholar at Hong Kong University of Science and Technology before undertaking post-doctoral research at Southern Methodist University (Dallas, Texas) and the University of Manitoba (Winnipeg, Manitoba). After spending many years working as an industrial research scientist in Winnipeg and Edmonton, Dr. Yao co-founded several companies, including a profitable contract research organization (CRO). Dr. Yao is a natural entrepreneur, building up companies from scratch and growing them to become sustainable and profitable businesses.
Leonard I. Wiebe, D.Sc., Ph.D. Chief Scientific Officer
Dr. Wiebe obtained his Ph.D. (1970) and D.Sc. (2002) from the University of Sydney (Australia) and holds Honorary Doctorates in Pharmaceutical Sciences from Meiji Pharmaceutical University (Japan) and Health Sciences University of Hokkaido (Japan). He was first appointed to the Faculty of Pharmacy and Pharmaceutical Sciences's academic staff at the University of Alberta in 1970, and after promotion to Associate (1973), Full Professor (1978) and Professor Emeritus in 2003. Dr. Wiebe held interim research appointments at the University of Tübingen, the German Cancer Research Center, and Heidelberg University in Germany, and the Royal Prince Alfred Hospital and Sydney University in Australia. He has served as an expert consultant to numerous Universities and international agencies, including the Volkswagen Foundation, Cancer UK, the Australian Atomic Energy Commission (now ANSTO), the Helmholtz Foundation, the Canadian Institutes for Health Research and the International Atomic Energy Agency. Dr. Wiebe was the Alexander von Humboldt Foundation's first Ambassador Scientist for Canada (2007-2012) and the first permanent Director of Biomedicine and Health at ANSTO. He is a member of the Editorial Boards of several international scientific journals published in his fields of interest.
Richard Fahlman, Ph.D., Scientific Advisor
Dr. Fahlman is an expert in applied and analytical biochemistry with 25 years of research experience. Dr. Fahlman earned his doctorate at Simon Fraser University, and completed post-doctoral research at the University of Colorado, Northwestern University and the University of British Columbia. He is currently Professor in the Department of Biochemistry, Adjunct Professor in the Department of Oncology and Director of the Alberta Proteomics and Mass Spectrometry core facility at the University of Alberta. He has served on the Scientific Advisory boards of several companies and is a current grant panel member for the Cancer Biology and Therapeutics panel for the Canadian Institutes for Health Research (CIHR) and the Canadian Cancer Society. His current research interests lie in autoimmunity and oncology, with a specific molecular focus on proteostasis mechanisms in these diseases. Dr. Fahlman is an inventor of two patents and an author of 61 publications.